Dexmedetomidine Maintains Renal Function in ICU Patients
Dexmedetomidine is a selective alpha-2 adrenergic agonist that is used as a sedative in the ICU. Emerging postoperative studies indicate that the parenteral agent may be renoprotective. While the exact mechanism by which dexmedetomidine exerts its renal-protective effect is not known, it is thought to be related to the drug's sympatholytic, anti-inflammatory, and cytoprotective properties. Read more.

ASPEN Injectable Lipid Emulsion Safety Recommendations in Neonates and Pediatric Patients
Injectable lipid emulsions provide energy, fatty acids, and substrates needed to help promote normal growth and development in children. However, their use is not without concern. There are special considerations concerning the use of these products in this population that differ from those for adults. Read more.

How Effective and Well-Tolerated Is Infliximab in the Management of IBD?
The development of monoclonal antibodies revolutionized the management of inflammatory bowel disease (IBD), which is associated with significant morbidity. Among these agents, infliximab, a monoclonal antibody, is one of the preferred treatment options. However, about one-half of patients who achieve clinical remission with infliximab relapse within 1 year of discontinuation. Read more.